Head to head
Quest Diagnostics vs Thermo Fisher Scientific
Side-by-side on the measures that matter, with a plain-English read. Full detail: DGX · TMO
DGX
Quest Diagnostics
258.28-0.31%
1-year price shape — +39% over the period
Quant Rating C · 83/100
vs
TMO
Thermo Fisher Scientific
669.54-2.79%
1-year price shape — +17% over the period
Quant Rating C · 61/100
1-year performance, rebased to 100
Thermo Fisher Scientific edges it on the scoreable measures. Thermo Fisher Scientific earns the most per share.
| DGX | TMO | |
|---|---|---|
| Snapshot | ||
| Sector | Diagnostics & Research | Diagnostics & Research |
| Last price | 258.28 | 669.54 |
| Change today | -0.31% | -2.79% |
| 1-year return | +39.5% | +17.2% |
| Market cap | $28.42B | $248.08B |
| 52-week range | 168.34 – 263.19 | 434.50 – 727.56 |
| Valuation | ||
| P/E (TTM) | 25.73 | 35.31 |
| P/E percentile, own 5-yr range | 98th | 89th |
| P/B | 3.72 | 4.53 |
| Dividend yield | 1.31% | 0.27% |
| Profitability & growth | ||
| EPS (TTM) | 8.75 | 17.74 |
| Net profit (TTM) | $962.67M | $6.57B |
| Revenue (TTM) | $11.84B | $47.35B |
| Provider revenue period date | 2026-09-29 | 2026-09-25 |
| Revenue growth (YoY) | +10.0% | +9.1% |
| Gross margin | 33.1% | 41.1% |
| Operating margin | 14.6% | 18.7% |
| Net margin | 9.5% | 14.9% |
| Free cash flow (TTM) | $1.38B | $7.60B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-25 |
| Ownership & sentiment | ||
| Institutional ownership | 96.9% | 94.1% |
| Insider activity (12mo) | 38 buy / 10 sell | 20 buy / 30 sell |
| Short interest (% of float) | 3.4% | 1.3% |
| Analyst consensus | 50% buy / 50% hold (8) | 88% buy / 12% hold (16) |
| Analyst price target | $260 (+1%) | $778 (+16%) |
| StockVane view | ||
| StockVane Quant Rating | C (83) | C (61) |
| Company | ||
| Employees | 57,000 | 125,000 |
| Founded | 1990 | 1956 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.